Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
OBJECTIVE
To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolactone, in the treatment of hirsutism.


METHODS
Prospective randomized single-blinded study.


METHODS
A tertiary hirsutism clinic.


METHODS
Forty-two premenopausal patients with hirsutism were selected.


METHODS
Subjects were randomized to receive either 100 mg spironolactone and an oral contraceptive (OC) containing 150 microg desogestrel and 30 microg ethinyl E2 or 50 mg CPA daily on days 1 to 10 of the menstrual cycle, which was administered with 35 microg ethinyl E2 daily on days 1 to 21.


METHODS
Hirsutism scores were measured according to Ferriman-Gallwey scoring system and side effects were monitored for 9 months of treatment. Blood samples were taken at each visit for assessment of endocrine, biochemical, and hematologic parameters.


RESULTS
Hirsutism scores were decreaded significantly in both groups at the end of 9 months. The percent of change in hirsutism scores in CPA and spironolactone group were as follows: 19.23% +/- 14.77% and 24.48% +/- 14.27% at 3 months; 39.01% +/- 19.77% and 37.46% +/- 16.90% at 6 months; and 51.89% +/- 20.87% and 46.39% +/- 16.10% at 9 months, respectively. There was a trend toward a better response with CPA treatment, which did not achieve significance. None of the patients stopped treatment because of side effects.


CONCLUSIONS
The present data suggest that both spironolactone and CPA were similarly effective in treatment of hirsutism.
Erenus
M
M
Marmara University School of Medicine, Istanbul, Turkey.
Yücelten
D
D
Gürbüz
O
O
Durmuşoğlu
F
F
Pekin
S
S
D019326:17-alpha-Hydroxyprogesterone; D000293:Adolescent; D000328:Adult; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D017135:Desogestrel / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006908:Hydroxyprogesterones / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011446:Prospective Studies; D016037:Single-Blind Method; D013148:Spironolactone / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
D003280:Contraceptives, Oral, Synthetic; D006908:Hydroxyprogesterones; D000451:Mineralocorticoid Receptor Antagonists; D045167:Progesterone Congeners; D013148:Spironolactone; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D019326:17-alpha-Hydroxyprogesterone; D017135:Desogestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone